2025-07-20 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co (LLY), presented in a report format:

## Eli Lilly and Co (LLY) Stock Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **Ticker:** LLY
*   **Cumulative Return (LLY):** 247.32%
*   **Cumulative Return (VOO):** 96.72%
*   **Absolute Divergence:** 150.6%
*   **Relative Divergence:** 52.5% (This indicates LLY's outperformance is in the upper half of its historical range compared to VOO).

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period.  The relative divergence suggests this outperformance is substantial compared to its historical trends.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta  | Cap(B) |
| :----------- | :------- | :------ | :------- | :---- | :------- |
| 2015-2017    | 10.0%    | 56.3%   | -19.0%   | 0.0   | 75.8    |
| 2016-2018    | 39.0%    | 58.6%   | 21.0%    | -0.1  | 103.9   |
| 2017-2019    | 50.0%    | 58.6%   | 20.0%    | 0.3   | 118.0   |
| 2018-2020    | 52.0%    | 58.6%   | 33.0%    | 0.1   | 151.6   |
| 2019-2021    | 106.0%   | 60.6%   | 57.0%    | 0.2   | 248.0   |
| 2020-2022    | 98.0%    | 64.8%   | 96.0%    | 0.2   | 328.4   |
| 2021-2023    | 133.0%   | 64.8%   | 115.0%   | 0.3   | 523.3   |
| 2022-2024    | 150.0%   | 72.2%   | 124.0%   | 0.2   | 693.0   |
| 2023-2025    | 100.0%   | 76.8%   | 52.0%    | 0.2   | 692.8   |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  CAGR is exceptionally high in recent periods (2019-2024), indicating strong growth momentum.
*   **MDD (Maximum Drawdown):** The MDD has increased over time, suggesting higher volatility or risk associated with LLY.
*   **Alpha:** Consistently positive and increasing Alpha values from 2016 onwards indicate that LLY is generating excess returns compared to its benchmark. The Alpha increased significantly in 2020 and continued to remain high, indicating a period of exceptional outperformance.
*   **Beta:** Beta values close to 0 suggest that LLY's price movements are not strongly correlated with the overall market (S&P 500).
*   **Cap (B):**  The market capitalization has grown significantly, reflecting investor confidence and the company's growth.

### 2. Recent Price Movement

*   **Current Price:** $771.71
*   **Last Market Data:**  {'price': 771.71, 'previousClose': 761.5, 'change': 1.34} (Positive change indicates an upward price movement.)
*   **5-Day Moving Average:** 778.82
*   **20-Day Moving Average:** 780.36
*   **60-Day Moving Average:** 779.87

**Analysis:** The current price is below all three moving averages (5, 20, and 60 days), suggesting a short-term downward trend. However, the previous day's positive change indicates a potential rebound.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 48.59 (Neutral - neither overbought nor oversold)
*   **PPO:** -0.262 (Slightly negative, suggesting a slight downward trend in momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) (Cash Ratio: 0% on 2025-07-11) (Suggests a buy signal with caution due to the MRI value)
*   **Recent (20-day) Relative Divergence Change:** -3.2 (Negative change suggests a recent weakening in relative performance)
*   **Expected Return:** 146.4% (Long-term projected outperformance vs. S&P 500 if investing and holding for 2+ years)

**Analysis:** The MRI indicates a low-risk environment. The RSI is neutral. The recent decrease in relative divergence is a bearish signal. The negative PPO indicates slight downward trend, however, the Hybrid Signal suggests a buying opportunity, albeit with caution.  The high expected return suggests a strong belief in the company's long-term growth potential. The Last Market Data shows that the price increased a bit compared to the previous close, so it could indicate a rebound.

### 4. Recent News & Significant Events

*   **[2025-07-16]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-20]:** Analysts are discussing Eli Lilly's performance in the context of industry and global economic factors.
*   **[2025-07-19]:** Stock volatility influenced by recent news, earnings, or executive actions.
*   **[2025-07-17]:** Market experts highlight both risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The news indicates that LLY is currently subject to market scrutiny. Potential business developments and regulatory changes might explain the volatility.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
| :--------- | :--- | :--------- |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2024-04-30 | 2.49 | 8.77 B$    |
| 2025-05-01 | 2.49 | 8.77 B$    |

**Analysis:** Earnings per share (EPS) and revenue have generally increased from 2024-04-30 to 2025-05-01. The latest EPS figures of 3.07 and 2.49 (duplicate date) are relatively healthy. The revenue also saw significant growth during the same period.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :------------ |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE      |
| :--------- | :--------- | :------- |
| 2025-03-31 | $15.76B   | 17.50%   |
| 2024-12-31 | $14.19B   | 31.07%   |
| 2024-09-30 | $14.24B   | 6.81%    |
| 2024-06-30 | $13.56B   | 21.88%   |
| 2024-03-31 | $12.81B   | 17.51%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue shows a general upward trend over the quarters. The Profit Margin is exceptionally high and consistent above 80%, indicating strong operational efficiency.
*   **Capital and Profitability:** Equity has increased steadily, signifying a growing asset base. The Return on Equity (ROE) is volatile but generally healthy, with a peak in 2024-12-31.

### 7. 종합 Analysis

Eli Lilly and Co (LLY) has demonstrated exceptional performance, significantly outperforming the S&P 500. Strong revenue and earnings growth, high profitability, and positive analyst sentiment drive the positive performance.

**Key Points:**

*   **Strong Outperformance:** LLY is generating very high returns compared to the market.
*   **High Growth:** Recent CAGR values reflect the company's strong growth momentum.
*   **Volatility:** Increased MDD indicates higher risk.
*   **Positive Earnings Trend:**  Rising revenues and EPS figures contribute to the positive outlook.
*   **High Profitability:** Extremely high and consistent profit margins show efficient operations.
*   **Recent Price Weakness:** Current price is below moving averages, and relative divergence has recently decreased.
*   **Market Scrutiny:** News suggests ongoing business developments and regulatory considerations might be contributing to volatility.
*   **Long-Term Potential:** A High Expected Return with a caution indicator.
